Hyderabad-based pharmaceutical company Aurobindo Pharma is all set to announce its October-December (Q3 FY24) financial results on Saturday, February 10. Experts predict that the company will show a strong performance with strong sales growth in the US and European markets.
Analysts expect Aurobindo Pharma to report a consolidated net profit of Rs 904 crore for the fiscal third quarter, an increase of 84.1 percent over the same period last year. Analysts also expect the company’s revenue to rise to Rs 7,421 crore in the December quarter from Rs 6,407 crore.
Aurobindo Pharma Income Report
According to research, Aurobindo Pharma is expected to report earnings before interest, tax, depreciation and amortization (EBTDA) of Rs 1,566 crore, a growth of 64.2 percent over the same period last year.
The drugmaker’s third-quarter margin reached 21 percent, up 600 basis points from the same period last year. They also estimate revenue growth for the pharmaceutical company at 32 percent from the US market and 13 percent from the European market. Notably, Aurobindo Pharma generates 89 percent of its total revenue from foreign markets.